<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00306553</url>
  </required_header>
  <id_info>
    <org_study_id>CYT004-MelQbG10 03</org_study_id>
    <nct_id>NCT00306553</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytos Biotechnology AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytos Biotechnology AG</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a specific cellular immune response in melanoma&#xD;
      patients that have been vaccinated with a Melan-A VLP vaccine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Malignant Melanoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CYT004-MelQbG10</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide written informed consent.&#xD;
&#xD;
          -  Able and willing to complete all protocol requirements.&#xD;
&#xD;
          -  Age: 18 years and older.&#xD;
&#xD;
          -  Histological confirmed stage III or IV melanoma.&#xD;
&#xD;
          -  At least one confirmed detectable target lesion&#xD;
&#xD;
          -  HLA-A*0201 haplotype&#xD;
&#xD;
          -  Expected survival of at least 6 months.&#xD;
&#xD;
          -  Full recovery from surgery.&#xD;
&#xD;
          -  Able to undergo either CT scan or MRI scan for tumor assessment.&#xD;
&#xD;
          -  Wash-out period of 4 weeks after chemotherapy&#xD;
&#xD;
          -  All AEs form prior anticancer therapy have resolved to â‰¤ Grade 1.&#xD;
&#xD;
          -  Sexually active males should use adequate contraception throughout the study period&#xD;
             and 3 months thereafter.&#xD;
&#xD;
          -  Females of child bearing potential should use adequate contraception throughout the&#xD;
             study period and 3 months thereafter, that can be oral contraception or a&#xD;
             double-barrier local contraception (intra-uterine device plus condom or spermicidal&#xD;
             gel plus condom), and have a negative serum pregnancy test within 4 weeks prior to the&#xD;
             first dose of the vaccine.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing.&#xD;
&#xD;
          -  Use of an investigational drug within 30 days before enrolment.&#xD;
&#xD;
          -  Known or suspected brain metastases.&#xD;
&#xD;
          -  Current use of an immunosuppressive drug or any concomitant medication that could&#xD;
             potentially interfere with the study drug&#xD;
&#xD;
          -  Presence of significant cardiovascular, renal, pulmonary, endocrine, infectious,&#xD;
             neurological or bone marrow function disorders&#xD;
&#xD;
          -  Serum tests positive for HIV, HBV, HCV.&#xD;
&#xD;
          -  Active autoimmune diseases or severe allergies.&#xD;
&#xD;
          -  Current diagnosis or history of relevant and severe psychiatric disorder that&#xD;
             compromises the patient's ability to understand the patient information, to give&#xD;
             informed consent, to comply with the trial protocol or to complete the study.&#xD;
&#xD;
          -  Abuse of alcohol or other recreational drugs.&#xD;
&#xD;
          -  Previous vaccination with a Melan-A analog peptide.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Alexander Knuth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Oncology, Univerity Hospital Zuerich, CH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Dermatology, USZ</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology, USZ</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>March 23, 2006</study_first_submitted>
  <study_first_submitted_qc>March 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2006</study_first_posted>
  <last_update_submitted>September 18, 2006</last_update_submitted>
  <last_update_submitted_qc>September 18, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

